Piper Sandler analyst David Amsellem maintained a Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

On Wednesday, Piper Sandler reiterated its Overweight rating on shares ... NBIX), which is covered by analyst David Amsellem. With a market capitalization of $4.58 billion and a strong financial ...

Piper Sandler Companies (PIPR) came out with quarterly earnings of $4.80 per share, beating the Zacks Consensus Estimate of $3.62 per share. This compares to earnings of $4.03 per share a year ago.

Piper Sandler Companies reported robust financial results for Q4 2024, significantly surpassing analyst expectations. The company achieved earnings per share (EPS) of $4.80, exceeding the ...

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR) has released its most recent financial results. The complete earnings release can be found on the firm’s website at ...

Piper Sandler Companies reported robust fourth-quarter 2024 earnings, with earnings per share (EPS) of $4.8, surpassing the forecast of $3.93. The company's revenue reached $499 million ...